Tumors of the Esophagus

Sleisenger and Fordtran’s Gastrointestinal and Liver Disease- 2 Volume Set: Pathophysiology, Diagnosis, Management, Expert Consult Premium Edition - Enhanced Online Features and Print

Volumn , Issue , 2010, Pages 745-770

  Das, Ananya ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85124864986     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-6189-2.00046-9     Document Type: Chapter

References (237)

1. Atherfold PA., Jankowski JA Molecular biology of Barrett’s cancer Best Pract Res Clin Gastroenterol 20 2006 813-827(Ref 98.)
2. Coorley DA., Kerlikowske K., Verma R., Buffler P Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysis Gastroenterology 124 2003 47-56(Ref 62.)
3. Das A., Singh V., Fleischer DE., Sharma VK A comparison of endoscopic treatment and surgery in early esophageal cancer: An analysis of surveillance epidemiology and end results data Am J Gastroenterol 103 2008 1340-1345(Ref 186.)
4. Gebski V., Burmeister B., Smithers BM., et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis Lancet Oncol 8 2007 226-234(Ref 203.)
5. Guo JH., Teng GJ., Zhu GY., et al. Self-expandable esophageal stent loaded with 125I seeds: Initial experience in patients with advanced esophageal cancer Radiology 247 2008 574-581(Ref 220.)
6. Lagergren J., Bergstrom R., Lindgren A., Nyren O Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma N Engl J Med 18 340 1999 825-831(Ref 40.)
7. Larsson SC., Giovannucci E., Wolk A Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: A meta-analysis Gastroenterology 131 2006 1271-1283(Ref 17.)
8. Ngamruengphong S., Sharma VK., Das A Diagnostic yield of methylene blue chromoendoscopy for detecting specialized intestinal metaplasia and dysplasia in Barrett’s esophagus: A meta-analysis Gastrointest Endosc 69 2009 1021-1028(Ref 121.)
9. Rastogi A., Puli S., El-Serag HB., et al. Incidence of esophageal adenocarcinoma in patients with Barrett’s esophagus and high-grade dysplasia: A meta-analysis Gastrointest Endosc 67 2008 394-398(Ref 52.)
10. Stein HJ., Feith M., Bruecher BL., et al. Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection Ann Surg 242 2005 566-573(Ref 115.)
11. Steyerberg EW., Homs MY., Stokvis A., et al. Stent placement or brachytherapy for palliation of dysphagia from esophageal cancer: A prognostic model to guide treatment selection Gastrointest Endosc 62 2005 333-340(Ref 218.)
12. Takubo K., Aida J., Sawabe M Early squamous cell carcinoma of the oesophagus: The Japanese viewpoint Histopathology 51 2007 733-742(Ref 102.)
13. Wang KK., Sampliner RE., Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus Am J Gastroenterol 103 2008 788-797(Ref 44.)
14. Westerterp M., van Westreenen HL., Reitsma JB., et al. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy-Systematic review Radiology 236 2005 841-851(Ref 173.)
15. Wolfsen HC., Crook JE., Krishna M., et al. Prospective, controlled tandem endoscopy study of narrow band imaging for dysplasia detection in Barrett’s esophagus Gastroenterology 135 2008 24-31(Ref 128.)
16. Parkin DM., Bray F., Ferlay J., Pisani P Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74-108.
17. Garcia M., Jemal A., Ward EM., et al. Global cancer facts & figures 2007 2007 American Cancer Society Atlanta.
18. In: Ries LAG., Melbert D., Krapcho M., et al. SEER Cancer statistics review, 1975-2005 2008 National Cancer Institute Bethesda, MDhttp://seer.cancer.gov/csr/1975_2005/ based on November 2007 SEER data submission, posted to the SEER website.
19. Saidi F., Sepehr A., Fahimi S., et al. Oesophageal cancer among the Turkomans of northeast Iran Br J Cancer 83 2000 1249-1254.
20. Jansson C Socioeconomic factors and risk of esophageal adenocarcinoma: A nationwide Swedish case-control study Cancer Epidemiol Biomarkers Prev 14 2005 1754-1761.
21. Brown LM., Devesa SS., Chow WH Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age J Natl Cancer Inst 100 2008 1184-1187.
22. Pera M., Manterola C., Vidal O., Grande L Epidemiology of esophageal adenocarcinoma J Surg Oncol 92 2005 151-159.
23. Brown LM., Devesa SS Epidemiologic trends in esophageal and gastric cancer in the United States Surg Oncol Clin North Am 11 2002 235-256.
24. Bollschweiler E., Wolfgarten E., Gutschow C., Hölscher AH Demographic variations in the rising incidence of esophageal adenocarcinoma in white males Cancer 92 2001 549-555.
25. Mengesha B., Ergete W Staple Ethiopian diet and cancer of the oesophagus East Afr Med J 82 2005 353-356.
26. Isaacson C The change of the staple diet of black South Africans from sorghum to maize (corn) is the cause of the epidemic of squamous carcinoma of the oesophagus Med Hypotheses 64 2005 658-660.
27. de Boer JG., Yang H., Holcroft J., Skov K Chemoprotection against N-nitrosomethylbenzylamine-induced mutation in the rat esophagus Nutr Cancer 50 2004 168-173.
28. Wu IC., Lu CY., Kuo FC., et al. Interaction between cigarette, alcohol and betel nut use on esophageal cancer risk in Taiwan Eur J Clin Invest 36 2006 236-241.
29. Mark SD., Qiao YL., Dawsey SM., et al. Prospective study of serum selenium levels and incident esophageal and gastric cancers J Natl Cancer Inst 92 2000 1753-1763.
30. Blot WJ., Li JY., Taylor PR., et al. Nutrition intervention trials in Linxian, China: Supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population J Natl Cancer Inst 85 1993 1483-1492.
31. Abnet CC., Lai B., Qiao YL., et al. Zinc concentration in esophageal biopsy specimens measured by x-ray fluorescence and esophageal cancer risk J Natl Cancer Inst 97 2005 301-306.
32. Larsson SC., Giovannucci E., Wolk A Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis Gastroenterology 131 2006 1271-1283.
33. Li D., Diao Y., Li H., Fang X., Li H Association of the polymorphisms of MTHFR C677T, VDR C352T, and MPO G463A with risk for esophageal squamous cell dysplasia and carcinoma Arch Med Res 39 2008 594-600.
34. Tavani A., Bertuzzi M., Talamini R., et al. Coffee and tea intake and risk of oral, pharyngeal and esophageal cancer Oral Oncol 39 2003 695-700.
35. De Stefani E., Deneo-Pellegrini H., Ronco AL., et al. Food groups and risk of squamous cell carcinoma of the oesophagus: A case-control study in Uruguay Br J Cancer 89 2003 1209-1214.
36. Altieri A., Bosetti C., Gallus S., et al. Wine, beer and spirits and risk of oral and pharyngeal cancer: A case-control study from Italy and Switzerland Oral Oncol 40 2004 904-909.
37. Guo YM., Wang Q., Liu YZ., et al. Genetic polymorphisms in cytochrome P4502E1, alcohol and aldehyde dehydrogenases and the risk of esophageal squamous cell carcinoma in Gansu Chinese males World J Gastroenterol 14 2008 1444-1449.
38. Yokoyama A., Kato H., Yokoyama T., et al. Genetic polymorphisms of alcohol and aldehyde dehydrogenases and glutathione S-transferase M1 and drinking, smoking, and diet in Japanese men with esophageal squamous cell carcinoma Carcinogenesis 23 2002 1851-1859.
39. Zendehdel K., Nyrén O., Edberg A., Ye W Risk of esophageal adenocarcinoma in achalasia patients, a retrospective cohort study in Sweden Am J Gastroenterol 102 2007 1-5.
40. VonBrevern M., Hollstein MC., Risk JM., et al. Loss of heterozygosity in sporadic oesophageal tumours in the tylosis oesophageal cancer (TOC) gene region of chromosome 17q Oncogene 17 1998 2101-2105.
41. Rosa DD., Pasqualotto AC., Denning DW Chronic mucocutaneous candidiasis and oesophageal cancer Med Mycol 46 2008 85-91.
42. Erkal HS., Mendenhall WM., Amdur RJ., et al. Synchronous and metachronous squamous cell carcinomas of the head and neck mucosal sites J Clin Oncol 19 2001 1358-1362.
43. Petit T., Georges C., Jung GM., et al. Systematic esophageal endoscopy screening in patients previously treated for head and neck squamous-cell carcinoma Ann Oncol 12 2001 643-646.
44. Zablotska LB., Chak A., Das A., Neugut AI Increased risk of squamous cell esophageal cancer after adjuvant radiation therapy for primary breast cancer Am J Epidemiol 161 2005 330-337.
45. Syrjänen KJ HPV infections and oesophageal cancer J Clin Pathol 55 2002 721-728.
46. Kubo A., Levin TR., Block G., et al. Dietary antioxidants, fruits, and vegetables and the risk of Barrett’s esophagus Am J Gastroenterol 2008 May 20 [Epub ahead of print].
47. Kubo A., Corley DA Meta-analysis of antioxidant intake and the risk of esophageal and gastric cardia adenocarcinoma Am J Gastroenterol 102 2007 2323-2330.
48. Ibiebele TI., Hughes MC., O’Rourke P., et al. Cancers of the esophagus and carbonated beverage consumption: A population-based case-control study Cancer Causes Control 19 2008 577-584.
49. Freedman ND., Abnet CC., Leitzmann MF., et al. A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes Am J Epidemiol 165 2007 1424-1433.
50. Corley DA., Kubo A., Zhao W Abdominal obesity and the risk of esophageal and gastric cardia carcinomas Cancer Epidemiol Biomarkers Prev 17 2008 352-358.
51. Corley DA., Kubo A., Levin TR., et al. Abdominal obesity and body mass index as risk factors for Barrett’s esophagus Gastroenterology 133 2007 34-41.
52. Edelstein ZR., Farrow DC., Bronner MP., et al. Central adiposity and risk of Barrett’s esophagus Gastroenterology 133 2007 403-411.
53. Cook MB., Greenwood DC., Hardie LJ., et al. A systematic review and meta-analysis of the risk of increasing adiposity on Barrett’s esophagus Am J Gastroenterol 103 2008 292-300.
54. Smith M., Zhou M., Whitlock G., et al. Esophageal cancer and body mass index: Results from a prospective study of 220, 000 men in China and a meta-analysis of published studies Int J Cancer 122 2008 1604-1610.
55. Lagergren J., Bergstrom R., Lindgren A., Nyren O Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma N Engl J Med 18 340 1999 825-831.
56. Whiteman DC., Sadeghi S., Pandeya N., et al. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus Gut 57 2008 173-180.
57. Hirota WK., Loughney TM., Lazas DJ., et al. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data Gastroenterology 116 1999 277-285.
58. Zagari RM., Fuccio L., Wallander MA., et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: Loiano-Monghidoro study Gut 2008 Apr 18 [Epub ahead of print].
59. Wang KK., Sampliner RE., Practice Parameters Committee of the American College of Gastroenterology Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus Am J Gastroenterol 103 2008 788-797.
60. Playford RJ New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett’s oesophagus Gut 55 2006 442.
61. van Soest EM., Dieleman JP., Siersema PD., et al. Increasing incidence of Barrett’s oesophagus in the general population Gut 54 2005 1062-1066.
62. Post PN., Siersema PD., Van Dekken H Rising incidence of clinically evident Barrett’s oesophagus in the Netherlands: A nation-wide registry of pathology reports Scand J Gastroenterol 42 2007 17-22.
63. Hage M., Siersema PD., van Dekken H., et al. Oesophageal cancer incidence and mortality in patients with long-segment Barrett’s oesophagus after a mean follow-up of 12.7 years Scand J Gastroenterol 39 2004 1175-1179.
64. Sharma P., Falk GW., Weston AP., et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus Clin Gastroenterol Hepatol 4 2006 566-572.
65. Dulai GS., Shekelle PG., Jensen DM., et al. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett’s cohort Am J Gastroenterol 100 2005 775-783.
66. Wani S., Choi W., Sharma P Low-grade dysplasia in Barrett’s esophagus-An innocent bystander? Pro Endoscopy 39 2007 643-646.
67. Rastogi A., Puli S., El-Serag HB., et al. Incidence of esophageal adenocarcinoma in patients with Barrett’s esophagus and high-grade dysplasia: A meta-analysis Gastrointest Endosc 67 2008 394-398.
68. Yousef F., Cardwell C., Cantwell MM., et al. The incidence of esophageal cancer and high-grade dysplasia in Barrett’s esophagus: A systematic review and meta-analysis Am J Epidemiol 168 2008 237-249.
69. Anandasabapathy S., Jhamb J., Davila M., et al. Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia Cancer 109 2007 668-674.
70. Smith KJ., O’Brien SM., Smithers BM., et al. Interactions among smoking, obesity, and symptoms of acid reflux in Barrett’s esophagus Cancer Epidemiol Biomarkers Prev 14 2005 2481-2486.
71. Raghunath A., Hungin AP., Wooff D., Childs S Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: Systematic review BMJ 326 2003 737.
72. Raghunath AS., Hungin AP., Wooff D., Childs S Systematic review: The effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis Aliment Pharmacol Ther 20 2004 733-744.
73. Rokkas T., Pistiolas D., Sechopoulos P., et al. Relationship between Helicobacter pylori infection and esophageal neoplasia: A meta-analysis Clin Gastroenterol Hepatol 5 2007 1413-1417.
74. Rubenstein JH., Davis J., Marrero JA., Inadomi JM Relationship between diabetes mellitus and adenocarcinoma of the oesophagus and gastric cardia Aliment Pharmacol Ther 22 2005 267-271.
75. Moreels TG., van Vliet EP., et al. Down syndrome and esophageal cancer Dis Esophagus 20 2007 183-186.
76. Fortuny J., Johnson CC., Bohlke K., et al. Use of anti-inflammatory drugs and lower esophageal sphincter-relaxing drugs and risk of esophageal and gastric cancers Clin Gastroenterol Hepatol 5 2007 1154-1159.e3.
77. Coorley DA., Kerlikowske K., Verma R., Buffler P Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysis Gastroenterology 124 2003 47-56.
78. Su H., Hu N., Shih J., et al. Gene expression analysis of esophageal squamous cell carcinoma reveals consistent molecular profiles related to a family history of upper gastrointestinal cancer Cancer Res 63 2003 3872-3876.
79. Hu N., Su H., Li WJ., et al. Allelotyping of esophageal squamous-cell carcinoma on chromosome 13 defines deletions related to family history Genes Chromosomes Cancer 44 2005 271-278.
80. Chak A., Faulx A., Kinnard M., et al. Identification of Barrett’s esophagus in relatives by endoscopic screening Am J Gastroenterol 99 2004 2107-2114.
81. Chak A., Ochs-Balcom H., Falk G., et al. Familiality in Barrett’s esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction Cancer Epidemiol Biomarkers Prev 15 2006 1668-1673.
82. Hiyama T., Yoshihara M., Tanaka S., Chayama K Genetic polymorphisms and esophageal cancer risk Int J Cancer 121 2007 1643-1658.
83. von Rahden BH., Stein HJ., Feith M., et al. Overexpression of TGF-beta1 in esophageal (Barrett’s) adenocarcinoma is associated with advanced stage of disease and poor prognosis Mol Carcin 45 2006 786-794.
84. Gibson MK., Abraham SC., Wu TT., et al. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy Clin Cancer Res 9 2003 6461-6468.
85. Fukuchi M., Miyazaki T., Fukai Y., et al. Plasma level of transforming growth factor beta1 measured from the azygos vein predicts prognosis in patients with esophageal cancer Clin Cancer Res 10 2004 2738-2741.
86. Natsugoe S., Xiangming C., Matsumoto M., et al. Smad4 and transforming growth factor beta1 expression in patients with squamous cell carcinoma of the esophagus Clin Cancer Res 8 2002 1838-1842.
87. Brien TP., Odze RD., Sheehan CE., et al. HER-2/neu gene amplification by FISH predicts poor survival in Barrett’s esophagus-associated adenocarcinoma Hum Pathol 31 2000 35-39.
88. Wang KL., Wu TT., Choi IS., et al. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: Association with poor outcome Cancer 109 2007 658-667.
89. Casson AG., Zheng Z., Evans SC., et al. Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma Cancer 104 2005 730-739.
90. Song Y., Zhao C., Dong L., et al. Overexpression of cyclin B1 in human esophageal squamous cell carcinoma cells induces tumor cell invasive growth and metastasis Carcinogenesis 29 2008 307-315.
91. Vieth M., Schneider-Stock R., Röhrich K., et al. INK4a-ARF alterations in Barrett’s epithelium, intraepithelial neoplasia and Barrett’s adenocarcinoma Virchows Arch 445 2004 135-141.
92. Bian YS., Osterheld MC., Fontolliet C., et al. p16 Inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett’s esophagus Gastroenterology 122 2002 1113-1121.
93. Nakamura T., Hayashi K., Ota M., et al. Expression of p21(Waf1/Cip1) predicts response and survival of esophageal cancer patients treated by chemoradiotherapy Dis Esophagus 17 2004 315-321.
94. Kawakami K., Brabender J., Lord RV., et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma J Natl Cancer Inst 92 2000 1805-1811.
95. Clément G., Braunschweig R., Pasquier N., et al. Methylation of APC, TIMP3, and TERT: A new predictive marker to distinguish Barrett’s oesophagus patients at risk for malignant transformation J Pathol 208 2006 100-107.
96. Schneider PM., Stoeltzing O., Roth JA., et al. P53 Mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett’s esophagus Clin Cancer Res 6 2000 3153-3158.
97. Iravani S., Zhang HQ., Yuan ZQ., et al. Modification of insulinlike growth factor 1 receptor, c-Src, and Bcl-XL protein expression during the progression of Barrett’s neoplasia Hum Pathol 34 2003 975-982.
98. Abdel-Latif MM., O’Riordan J., Windle HJ., et al. NF-kappa B activation in esophageal adenocarcinoma: Relationship to Barrett’s metaplasia, survival, and response to neoadjuvant chemoradiotherapy Ann Surg 239 2004 491-500.
99. Sagatys E., Garrett CR., Boulware D., et al. Activation of the serine/threonine protein kinase Akt during the progression of Barrett neoplasia Hum Pathol 38 2007 1526-1531.
100. Beales IL., Ogunwobi O., Cameron E., et al. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett’s oesophagus and contributes to increased proliferation and inhibition of apoptosis: A histopathological and functional study BMC Cancer 7 2007 Jun 8 97.
101. Lord RV., Salonga D., Danenberg KD., et al. Telomerase reverse transcriptase expression is increased early in the Barrett’s metaplasia, dysplasia, adenocarcinoma sequence J Gastrointest Surg 4 2000 135-142.
102. Nair KS., Naidoo R., Chetty R Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value J Clin Pathol 58 2005 343-351.
103. Tanioka Y., Yoshida T., Yagawa T., et al. Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer Br J Cancer 89 2003 2116-2121.
104. Buskens CJ., van Rees BP., Sivula A Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus Gastroenterology 122 2002 1800-1807.
105. Buskens CJ., Sivula A., van Rees BP., et al. Comparison of cyclooxygenase 2 expression in adenocarcinomas of the gastric cardia and distal oesophagus Gut 52 2003 1678-1683.
106. Evans SC., Gillis A., Geldenhuys L., et al. Microsatellite instability in esophageal adenocarcinoma Cancer Lett 212 2004 241-251.
107. Fang M., Lew E., Klein M., et al. DNA abnormalities as marker of risk for progression of Barrett’s esophagus to adenocarcinoma: Image cytometric DNA analysis in formalin-fixed tissues Am J Gastroenterol 99 2004 1887-1894.
108. Su M., Chin SF., Li XY., et al. Comparative genomic hybridization of esophageal adenocarcinoma and squamous cell carcinoma cell lines Dis Esophagus 19 2006 10-14.
109. Zagorowicz E., Jankowski J Molecular changes in the progression of Barrett’s oesophagus Postgrad Med J 83 2007 529-535.
110. Wong NA., Wilding J., Bartlett S., et al. CDX1 is an important molecular mediator of Barrett’s metaplasia Proc Natl Acad Sci U S A 102 2005 7565-7570.
111. Kazumori H., Ishihara S., Rumi MA., et al. Bile acids directly augment caudal related homeobox gene Cdx2 expression in oesophageal keratinocytes in Barrett’s epithelium Gut 55 2006 16-25.
112. Eda A., Osawa H., Yanaka I., et al. Expression of homeobox gene CDX2 precedes that of CDX1 during the progression of intestinal metaplasia J Gastroenterol Hepatol 37 2002 94-100.
113. Atherfold PA., Jankowski JA Molecular biology of Barrett’s cancer Best Pract Res Clin Gastroenterol 20 2006 813-827.
114. Schlemper RJ., Dawsey SM., Itabashi M., et al. Differences in diagnostic criteria for esophageal squamous cell carcinoma between Japanese and Western pathologists Cancer 88 2000 996-1006.
115. Gabbert HE., Shimoda T., Hainaut P., et al. Squamous cell carcinoma of the oesophagus In: Hamilton SR., Aaltonen LA World Health Organization of Tumours. Pathology and genetics. Tumours of the digestive system 2000 IARC Press Lyon (France) 9-30.
116. Tajima Y., Nakanishi Y., Tachimori Y., et al. Significance of involvement by squamous cell carcinoma of the ducts of esophageal submucosal glands: Analysis of 201 surgically resected superficial squamous cell carcinoma Cancer 89 2000 248-254.
117. Takubo K., Aida J., Sawabe M Early squamous cell carcinoma of the oesophagus: The Japanese viewpoint Histopathology 51 2007 733-742.
118. Ludeman L., Shepherd NA Serosal involvement in gastrointestinal cancer: Its assessment and significance Histopathology 47 2005 123-131.
119. Downs-Kelly E., Mendelin JE., Bennett AE., et al. Poor interobserver agreement in the distention of high-grade dysplasia and adenocarcinoma in pretreatment Barrett’s esophagus biopsies Am J Gastroenterol 103 2008 2333-2340.
120. Hornick JL., Odze RD Neoplastic precursor lesions in Barrett’s esophagus Gastroenterol Clin North Am 36 2007 775-796.
121. Odze RD Diagnosis and grading of dysplasia in Barrett’s oesophagus J Clin Pathol 59 2006 1029-1038.
122. Srivastava A., Hornick JL., Li X., et al. Loss of goblet cell differentiation occurs with the progression of dysplasia in Barrett’s esophagus [abstract] Gastroenterology 130 2006 A-264.
123. Lomo LC., Blount PL., Sanchez CA., et al. Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett’s esophagus cohort Am J Surg Pathol 30 2006 423-435.
124. Lörinc E., Jakobsson B., Landberg G., Veress B Ki67 and p53 immunohistochemistry reduces interobserver variation in assessment of Barrett’s oesophagus Histopathology 46 2005 642-648.
125. Skacel M., Petras RE., Rybicki LA., et al. p53 Expression in low grade dysplasia in Barrett’s esophagus: Correlation with interobserver agreement and disease progression Am J Gastroenterol 97 2002 2508-2513.
126. Dorer R., Odze RD AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett’s esophagus, ulcerative colitis, and Crohn’s disease Am J Surg Pathol 30 2006 871-877.
127. Lisovsky M., Falkowski O., Bhuiya T Expression of alpha-methylacyl-coenzyme A racemase in dysplastic Barrett’s epithelium Hum Pathol 37 2006 1601-1606.
128. Westerterp M., Koppert L., Buskens CJ., et al. Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction Virchows Arch 446 2005 497-504.
129. Bollschweiler E., Baldus SE., Schröder W., et al. High rate of lymph-node metastasis in submucosal esophageal squamous-cell carcinomas and adenocarcinomas Endoscopy 38 2006 149-156.
130. Stein HJ., Feith M., Bruecher BL., et al. Early esophageal cancer: Pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection Ann Surg 242 2005 566-573.
131. Kim SH., Lee JM., Han JK., et al. Three-dimensional MDCT imaging and CT esophagography for evaluation of esophageal tumors: preliminary study Eur Radiol 16 2006 2418-2426.
132. The Paris endoscopic classification of superficial neoplastic lesions: Esophagus, stomach, and colon Gastrointest Endosc 58 2003 S3-43.
133. Fritcher EG., Brankley SM., Kipp BR., et al. A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett’s esophagus Hum Pathol 39 2008 1128-1135.
134. Dubuc J., Legoux JL., Winnock M., et al. Endoscopic screening for esophageal squamous-cell carcinoma in high-risk patients: A prospective study conducted in 62 French endoscopy centers Endoscopy 38 2006 690-695.
135. Canto MI., Kalloo A Chromoendoscopy for Barrett’s esophagus in the twenty-first century: to stain or not to stain? Gastrointest Endosc 64 2006 200-205.
136. Ngamruengphong S., Sharma VK., Das A Diagnostic yield of methylene blue chromoendoscopy for detecting specialized intestinal metaplasia and dysplasia in Barrett’s esophagus: A meta-analysis Gastrointest Endosc 69 2009 1021-1028.
137. Hoffman A., Kiesslich R., Bender A., et al. Acetic acid-guided biopsies after magnifying endoscopy compared with random biopsies in the detection of Barrett’s esophagus: A prospective randomized trial with crossover design Gastrointest Endosc 64 2006 1-8.
138. Hamamoto Y., Endo T., Nosho K., et al. Usefulness of narrow-band imaging endoscopy for diagnosis of Barrett’s esophagus J Gastroenterol 39 2004 14-20.
139. Pohl J., May A., Rabenstein T., et al. Comparison of computed virtual chromoendoscopy and conventional chromoendoscopy with acetic acid for detection of neoplasia in Barrett’s esophagus Endoscopy 39 2007 594-598.
140. Kara MA., Peters FP., Rosmolen WD., et al. High-resolution endoscopy plus chromoendoscopy or narrow-band imaging in Barrett’s esophagus: A prospective randomized crossover study Endoscopy 37 2005 929-936.
141. Sharma P., Bansal A., Mathur S., et al. The utility of a novel narrow band imaging endoscopy system in patients with Barrett’s esophagus Gastrointest Endosc 64 2006 167-175.
142. Goda K., Tajiri H., Ikegami M., et al. Usefulness of magnifying endoscopy with narrow band imaging for the detection of specialized intestinal metaplasia in columnar-lined esophagus and Barrett’s adenocarcinoma Gastrointest Endosc 65 2007 36-46.
143. Wolfsen HC., Crook JE., Krishna M., et al. Prospective, controlled tandem endoscopy study of narrow band imaging for dysplasia detection in Barrett’s esophagus Gastroenterology 135 2008 24-31.
144. Curvers W., Baak L., Kiesslich R., et al. Chromoendoscopy and narrow-band imaging compared with high-resolution magnification endoscopy in Barrett’s esophagus Gastroenterology 134 2008 670-679.
145. Guelrud M., Ehrlich EE Enhanced magnification endoscopy in the upper gastrointestinal tract Gastrointest Endosc Clin North Am 14 2004 461-473.
146. Kiesslich R., Gossner L., Goetz M., et al. In vivo histology of Barrett’s esophagus and associated neoplasia by confocal laser endomicroscopy Clin Gastroenterol Hepatol 4 2006 979-987.
147. Pohl H., Koch M., Khalifa A., et al. Evaluation of endocytoscopy in the surveillance of patients with Barrett’s esophagus Endoscopy 39 2007 492-496.
148. Fujishiro M., Takubo K., Sato Y., et al. Potential and present limitation of endocytoscopy in the diagnosis of esophageal squamous-cell carcinoma: a multicenter ex vivo pilot study Gastrointest Endosc 66 2007 551-555.
149. Chemaly M., Scalone O., Durivage G., et al. Miniprobe EUS in the pretherapeutic assessment of early esophageal neoplasia Endoscopy 40 2008 2-6.
150. May A., Günter E., Roth F., et al. Accuracy of staging in early oesophageal cancer using high resolution endoscopy and high resolution endosonography: A comparative, prospective, and blinded trial Gut 53 2004 634-640.
151. Evans JA., Poneros JM., Bouma BE., et al. Optical coherence tomography to identify intramucosal carcinoma and high-grade dysplasia in Barrett’s esophagus Clin Gastroenterol Hepatol 4 2006 38-43.
152. Isenberg GA., Sivak MV Jr., Chak A., et al. Accuracy of endoscopic optical coherence tomography in the detection of dysplasia in Barrett’s esophagus: A prospective, double-blinded study Gastrointest Endosc 62 2005 825-831.
153. Vakoc BJ., Shishko M., Yun SH., et al. Comprehensive esophageal microscopy by using optical frequency-domain imaging Gastrointest Endosc 65 2007 898-905.
154. Georgakoudi I., Jacobson BC., Van Dam J., et al. Fluorescence, reflectance, and light-scattering spectroscopy for evaluating dysplasia in patients with Barrett’s esophagus Gastroenterology 120 2001 1620-1629.
155. Shetty G., Kendall C., Shepherd N., et al. Raman spectroscopy: elucidation of biochemical changes in carcinogenesis of oesophagus Br J Cancer 94 2006 1460-1464.
156. Shaheen NJ., Provenzale D., Sandler RS Upper endoscopy as a screening and surveillance tool in esophageal adenocarcinoma: A review of the evidence Am J Gastroenterol 97 2002 1319-1327.
157. Dulai GS., Guha S., Kahn KL., et al. Preoperative prevalence of Barrett’s esophagus in esophageal adenocarcinoma: A systematic review Gastroenterology 122 2002 26-33.
158. Gerson LB., Ullah N., Hastie T., Goldstein MK Does cancer risk affect health-related quality of life in patients with Barrett’s esophagus? Gastrointest Endosc 65 2007 16-25.
159. Shaheen NJ., Dulai GS., Ascher B., et al. Effect of a new diagnosis of Barrett’s esophagus on insurance status Am J Gastroenterol 100 2005 577-580.
160. Inadomi JM., Sampliner R., Lagergren J., et al. Screening and surveillance for Barrett esophagus in high-risk groups: A cost-utility analysis Ann Intern Med 138 2003 176-186.
161. Soni A., Sampliner RE., Sonnenberg A Screening for high-grade dysplasia in gastroesophageal reflux disease: Is it cost effective? Am J Gastroenterol 95 2000 2086-2093.
162. Gerson LB., Groeneveld PW., Triadafilopoulos G Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease Clin Gastroenterol Hepatol 2 2004 868-879.
163. Wang LD., Yang HH., Fan ZM., et al. Cytological screening and 15 years’ follow-up (1986-2001) for early esophageal squamous cell carcinoma and precancerous lesions in a high-risk population in Anyang County, Henan Province, Northern China Cancer Detect Prev 29 2005 317-322.
164. Williams GH., Swinn R., Prevost AT., et al. Diagnosis of oesophageal cancer by detection of minichromosome maintenance 5 protein in gastric aspirates Br J Cancer 91 2004 714-719.
165. Atkinson M., Das A., Faulx A., et al. Ultrathin esophagoscopy in screening for Barrett’s esophagus at a Veterans Administration hospital: Easy access does not lead to referrals Am J Gastroenterol 103 2008 92-97.
166. Galmiche JP., Sacher-Huvelin S., Coron E., et al. Screening for esophagitis and Barrett’s esophagus with wireless esophageal capsule endoscopy: A multicenter prospective trial in patients with reflux symptoms Am J Gastroenterol 103 2008 538-545.
167. Ramirez FC., Shaukat MS., Young MA., et al. Feasibility and safety of string, wireless capsule endoscopy in the diagnosis of Barrett’s esophagus Gastrointest Endosc 61 2005 741-746.
168. Sharma P., Sidorenko EI Are screening and surveillance for Barrett’s oesophagus really worthwhile? Gut 54 2005 i27-i32.
169. Garside R., Pitt M., Somerville M., et al. Surveillance of Barrett’s oesophagus: Exploring the uncertainty through systematic review, expert workshop and economic modeling Health Technol Assess 10 2006 1-142.
170. Corley DA., Levin TR., Habel LA., et al. Surveillance and survival in Barrett’s adenocarcinoma: A population-based study Gastroenterology 122 2002 633-640.
171. Cooper GS Endoscopic screening and surveillance for Barrett’s esophagus: Can claims data determine its effectiveness? Gastrointest Endosc 57 2003 914-915.
172. Macdonald CE., Wicks AC., Playford RJ., et al. Final results from 10 year cohort of patients undergoing surveillance for Barrett’s oesophagus: Observational study BMJ 321 2000 1252-1255.
173. Ell C., May A., Pech O., et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett’s cancer) Gastrointest Endosc 65 2007 3-10.
174. Larghi A., Lightdale CJ., Memeo L., et al. EUS followed by EMR for staging of high-grade dysplasia and early cancer in Barrett’s esophagus Gastrointest Endosc 62 2005 16-23.
175. Bhutani MS., Barde CJ., Markert RJ., Gopalswamy N Length of esophageal cancer and degree of luminal stenosis during upper endoscopy predict T stage by endoscopic ultrasound Endoscopy 34 2002 461-463.
176. Romagnuolo J., Scott J., Hawes RH., et al. Helical CT versus EUS with fine needle aspiration for celiac nodal assessment in patients with esophageal cancer Gastrointest Endosc 55 2002 648-654.
177. Dave UR., Williams AD., Wilson JA., et al. Esophageal cancer staging with endoscopic MR imaging: pilot study Radiology 230 2004 281-286.
178. van Vliet EP., Heijenbrok-Kal MH., Hunink MG., et al. Staging investigations for oesophageal cancer: A meta-analysis Br J Cancer 98 2008 547-557.
179. Das A., Chak A Role of endoscopic ultrasonography in the staging of esophageal cancer: A review Curr Opin Gastroenterol 19 2003 474-476.
180. Eloubeidi MA Routine EUS-guided FNA for preoperative nodal staging in patients with esophageal carcinoma: Is the juice worth the squeeze? Gastrointest Endosc 63 2006 212-214.
181. Pfau PR., Ginsberg GG., Lew RJ., et al. Endoscopic ultrasound predictors of long term survival in esophageal carcinoma Gastrointest Endosc 53 2001 463-469.
182. Harewood GC., Kumar KS Assessment of clinical impact of endoscopic ultrasound on esophageal cancer Gastroenterol Hepatol 19 2004 433-439.
183. Das A., Chak A., Sivak MV Jr., et al. Endoscopic ultrasonography and prognosis of esophageal cancer Clin Gastroenterol Hepatol 4 2006 695-700.
184. Duong CP., Hicks RJ., Weih L., et al. FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer Eur J Nucl Med Mol Imaging 33 2006 770-778.
185. McDonough PB., Jones DR., Shen KR., et al. Does FDG-PET add information to EUS and CT in the initial management of esophageal cancer? A prospective single center study Am J Gastroenterol 103 2008 570-574.
186. Christensen D The Will Rogers phenomenon roping the effects of a new cancer staging system J Natl Cancer Inst 95 2003 1105-1106.
187. Wallace MB., Nietert PJ., Earle C., et al. An analysis of multiple staging management strategies for carcinoma of the esophagus: Computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy Ann Thorac Surg 74 2002 1026-1032.
188. Westerterp M., van Westreenen HL., Reitsma JB., et al. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy-Systematic review Radiology 236 2005 841-851.
189. Das A., Chak A Reassessment of patients with esophageal cancer after neoadjuvant therapy Endoscopy 38 2006 S13-S17.
190. Weber WA., Ott K., Becker K., et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging J Clin Oncol 19 2001 3058-3065.
191. Cerfolio RJ., Bryant AS., Ohja B., et al. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy J Thorac Cardiovasc Surg 29 2005 1232-1241.
192. Heath EI., Canto MI., Piantadosi S., et al. Secondary chemoprevention of Barrett’s esophagus with celecoxib: Results of a randomized trial J Natl Cancer Inst 99 2007 545-557.
193. Limburg PJ., Wei W., Ahnen DJ., et al. Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib Gastroenterology 129 2005 863-873.
194. May A., Gossner L., Behrens A., et al. A prospective randomized trial of two different endoscopic resection techniques for early stage cancer of the esophagus Gastrointest Endosc 58 2003 167-175.
195. Ciocirlan M., Lapalus MG., Hervieu V., et al. Endoscopic mucosal resection for squamous premalignant and early malignant lesions of the esophagus Endoscopy 39 2007 Jan 24-29.
196. ASGE Technology committee., Kantsevoy SV., Adler DG., et al. Endoscopic mucosal resection and endoscopic submucosal dissection Gastrointest Endosc 68 2008 11-18.
197. Ishihara R., Iishi H., Uedo N., et al. Comparison of EMR and endoscopic submucosal dissection for en bloc resection of early esophageal cancers in Japan Gastrointest Endosc 2008 Jul 10 [Epub ahead of print].
198. Pacifico RJ., Wang KK., Wongkeesong LM., et al. Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett’s esophagus Clin Gastroenterol Hepatol 1 2003 252-257.
199. Pech O., Gossner L., May A., et al. Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett’s cancer and high-grade intraepithelial neoplasia Gastrointest Endosc 62 2005 24-30.
200. DeMeester SR EMR for intramucosal adenocarcinoma of the esophagus: Does one size fit all? Gastrointest Endosc 65 2007 14-15.
201. Das A., Singh V., Fleischer DE., Sharma VK A comparison of endoscopic treatment and surgery in early esophageal cancer: An analysis of surveillance epidemiology and end results data Am J Gastroenterol 103 2008 1340-1345.
202. Luketich JD., Alvelo-Rivera M., Buenaventura PO., et al. Minimally invasive esophagectomy: Outcomes in 222 patients Ann Surg 238 2003 486-494.
203. Nemoto K., Yamada S., Nishio M., et al. Results of radiation therapy for superficial esophageal cancer using the standard radiotherapy method recommended by the Japanese Society of Therapeutic Radiology and Oncology (JASTRO) Study Group Anticancer Res 26 2006 1507-1512.
204. Pasquier D., Mirabel X., Adenis A., et al. External beam radiation therapy followed by high-dose-rate brachytherapy for inoperable superficial esophageal carcinoma Int J Radiat Oncol Biol Phys 65 2006 1456-1461.
205. Shimizu Y., Kato M., Yamamoto J., et al. EMR combined with chemoradiotherapy: A novel treatment for superficial esophageal squamous-cell carcinoma Gastrointest Endosc 59 2004 199-204.
206. Nemoto K., Takai K., Ogawa Y., et al. Salvage radiation therapy for residual superficial esophageal cancer after endoscopic mucosal resection Int J Radiat Oncol Biol Phys 63 2005 1290-1294.
207. Enzinger PC., Mayer RJ Esophageal cancer N Engl J Med 349 2003 2241-2252.
208. Hulscher JB., van Sandick JW., de Boer AG., et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus N Engl J Med 347 2002 1662-1669.
209. Omloo JM., Lagarde SM., Hulscher JB., et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: Five-year survival of a randomized clinical trial Ann Surg 246 2007 992-1000.
210. Hulscher JB., Tijssen JG., Obertop H., van Lanschot JJ Transthoracic versus transhiatal resection for carcinoma of the esophagus: A meta-analysis Ann Thorac Surg 72 2001 306-313.
211. Chang AC., Ji H., Birkmeyer NJ., et al. Outcomes after transhiatal and transthoracic esophagectomy for cancer Ann Thorac Surg 85 2008 424-429.
212. Chang AC., Birkmeyer JD The volume-performance relationship in esophagectomy Thorac Surg Clin 16 2006 87-94.
213. Santin B., Kulwicki A., Price P Mortality rate associated with 56 consecutive esophagectomies performed at a “low-volume” hospital: Is procedure volume as important as we are trying to make it? J Gastrointest Surg 12 2008 1346-1350.
214. Sun XD., Yu JM., Fan XL., et al. Randomized clinical study of surgery versus radiotherapy alone in the treatment of resectable esophageal cancer in the chest Zhonghua Zhong Liu Za Zhi 28 2006 784-787.
215. Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev 2006; CD002092.
216. Minsky BD., Pajak TF., Ginsberg RJ., et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy Clin Oncol 20 2002 1167-1174.
217. Urschel JD., Vasan H A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer Am J Surg 185 2003 538-543.
218. Gebski V., Burmeister B., Smithers BM., et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis Lancet Oncol 8 2007 226-234.
219. Stahl M., Stuschke M., Lehmann N., et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus J Clin Oncol 23 2005 2310-2317.
220. Bedenne L., Michel P., Bouché O., et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102 J Clin Oncol 25 2007 1160-1168.
221. Cunningham D., Starling N., Rao S., et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 2008 36-46.
222. Dragovich T., McCoy S., Fenoglio-Preiser CM., et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127 J Clin Oncol 24 2006 4922-4927.
223. Lecleire S., Di Fiore F., Antonietti M., et al. Undernutrition is predictive of early mortality after palliative self-expanding metal stent insertion in patients with inoperable or recurrent esophageal cancer Gastrointest Endosc 64 2006 479-484.
224. Barrichello SA., De Moura EG., Couto DS., Sakai P Comparison of the safety and efficacy of two methods of stent placement in esophageal malignant strictures: With fluoroscopy and without fluoroscopy taken in consideration [Abstract] Gastrointest Endosc 67 2008 A283-A284.
225. Wenger U., Johnsson E., Arnelo U., et al. An antireflux stent versus conventional stents for palliation of distal esophageal or cardia cancer: a randomized clinical study Surg Endosc 20 2006 1675-1680.
226. Sabharwal T., Gulati MS., Fotiadis N., et al. Randomised comparison of the FerX Ella antireflux stent and the ultraflex stent: Proton pump inhibitor combination for prevention of post-stent reflux in patients with esophageal carcinoma involving the esophago-gastric junction J Gastroenterol Hepatol 23 2008 723-728.
227. Verschuur EM., Homs MY., Steyerberg EW., et al. A new esophageal stent design (Niti-S stent) for the prevention of migration: A prospective study in 42 patients Gastrointest Endosc 63 2006 134-140.
228. Conio M., Repici A., Battaglia G., et al. A randomized prospective comparison of self-expandable plastic stents and partially covered self-expandable metal stents in the palliation of malignant esophageal dysphagia Am J Gastroenterol 102 2007 2667-2677.
229. Siersma P., Hop W., van Blankenstein M., et al. A comparison of 3 types of covered metal stents for the palliation of patients with dysphagia caused by esophagogastric carcinoma: A prospective, randomized study Gastrointest Endosc 54 2001 145-153.
230. Verschuur EM., Repici A., Kuipers EJ., et al. New design esophageal stents for the palliation of dysphagia from esophageal or gastric cardia cancer: A randomized trial Am J Gastroenterol 103 2008 304-312.
231. Balazs A., Kupcsulik PK., Galambos Z Esophagorespiratory fistulas of tumorous origin: Non-operative management of 264 cases in a 20-year period Eur J Cardiothorac Surg 2008 Aug 2 [Epub ahead of print].
232. Homs MY., Steyerberg EW., Eijkenboom WM., et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: Multicentre randomised trial Lancet 364 2004 1497-1504.
233. Steyerberg EW., Homs MY., Stokvis A., et al. Stent placement or brachytherapy for palliation of dysphagia from esophageal cancer: A prognostic model to guide treatment selection Gastrointest Endosc 62 2005 333-340.
234. da Silveira EB., Artifon EL Cost-effectiveness of palliation of unresectable esophageal cancer Dig Dis Sci 2008 Jun 4 [Epub ahead of print].
235. Guo JH., Teng GJ., Zhu GY., et al. Self-expandable esophageal stent loaded with 125I seeds: Initial experience in patients with advanced esophageal cancer Radiology 247 2008 574-581.
236. Jobe BA., Enestvedt CK., Thomas CR Jr Disease-specific multidisciplinary care: A natural progression in the management of esophageal cancer Dis Esophagus 19 2006 417-418.
237. D’Amato G., Steinert DM., McAuliffe JC., Trent JC Update on the biology and therapy of gastrointestinal stromal tumors Cancer Control 12 2005 44-56.